Navigation Links
USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network

MADRID and WALTHAM, Mass., May 25, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) and Labec Pharma SA today announced that USP Hospitales now offers the innovative Heart Health Genetic Test, developed by Interleukin Genetics, at San Jose, USP Hospitales, the flagship hospital in Madrid, and will soon make it available throughout their hospital network. The test identifies single nucleotide variations in two Interleukin-1 (IL-1) genes that lead to a greater predisposition of cardiovascular events, based on an excessive inflammatory response. Labec will distribute the test through an exclusive license in Spain and Portugal under the CardioHealth™ brand.  

"We are pleased that one of the most renowned hospital systems in Spain will make the Heart Health Genetic Test available to its patients," said Lewis H. Bender, chief executive officer, Interleukin Genetics. "Heart disease is largely preventable and the earlier one recognizes their risks, especially their genetic risk, the sooner improved monitoring and prevention can be established."

"Labec Pharma has been working to provide information to leading cardiovascular disease experts in Spain and Portugal about the benefits of the CardioHealth Test," said Javier de Echevarria, chief executive officer at Labec Pharma. "Heart disease is a major problem in Spain and this test has the potential to identify those at greatest risk to allow for improved care. Providing easy access to this vital information will enable patients to take control of their heart health by enacting lifestyle changes to manage their risk factors."

About Heart Disease in SpainInflammation is an important risk factor for heart disease. Some genetic inflammation patterns are responsible for many cardiac events, including heart attacks. In Spain, 56 percent of the population presents an increased risk for developing cardiovascular disease. Cardiovascular disease is the major cause of death in men and women in industrialized countries and is responsible for 31.7 percent of all deaths in Spain (INE data March 2010).

About the CardioHealth Test in SpainThe CardioHealth™ Genetic Test was developed by Interleukin Genetics and reveals whether there is an increased risk of heart attack due to increased Interleukin-1 based inflammation. This simple, quick and painless test evaluates single nucleotide polymorphisms in two genes (Interleukin-1 Alpha and Interleukin-1 Beta) that are key in determining a greater predisposition to excessive levels of inflammation. The results are based on two clinical studies, one in the U.S. and one in Europe, that identified genetic patterns to indicate whether a person has more or less of a probability to suffer a heart attack as a result of this inflammatory activity.

Buccal epithelial cells from a cheek swab are collected for analysis and sent to Interleukin's U.S. headquarters for analysis. After three to four weeks, patients receive a complete report in Spanish outlining their cardiovascular genetic risk. The CardioHealth Genetic Test allows for the detection of an abnormally high risk in people at early age and has utility in the prevention of disease by promoting healthier lifestyles. If the inflammatory genetic factors related to cardiovascular disease are detected in time, one can take appropriate measures to reduce risk.

About Interleukin Genetics Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. In addition to the Heart Health Genetic Test, Interleukin Genetics' products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility - sold through dentists - and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).  For more information, please visit USP HospitalesWith a network of 12 hospitals and 20 diagnosis and day surgery clinics, head offices in Madrid and a presence throughout most of Spain, USP Hospitales has consolidated its position as the number one Spanish private hospital group. The cornerstones of its expansion have been quality healthcare, cutting-edge technology and rigorous professional standards. Today, USP Hospitales has 4,000 medical professionals who provide treatment to over two million patients every year. Furthermore, the Group's prime positioning in popular tourism areas and major cities has led it to develop an important programme, USP International Services, for providing healthcare to patients from abroad, assisted by translators specialising in medicine. USP Hospitales' commitment to society and to providing the highest quality of healthcare has built prestige for the company brand, which over the years, has received many important awards in recognition of its work. For further information about USP Hospitales and its products, visit

About Labec PharmaLabec Pharma is an important Spanish distributor of in-vitro diagnosis tests with a presence in Europe and Latin America. The Firm's focus is to identify and distribute the most state-of-the-art diagnosis technologies. Labec Pharma has numerous agreements with main hospitals and reference laboratories in Spain and Portugal to make these tests available to physicians and patients. Among the different tests distributed by Labec Pharma: CardioHealth is a cardiovascular risk genetic test and HPV OncoTect is a test for early diagnosis of cervical cancer. The main office of Labec Pharma is based in Madrid. For further information about Labec Pharma and its products, visit or contact our press relations office.

Certain statements contained herein are "forward-looking" statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2010 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.Contacts:Interleukin Media:

Interleukin Investors:

Labec Pharma:Jon Siegal / Kirsten Fallon

Eliot Lurier

Javier de EchevarriaSchwartz Communications

Interleukin Genetics

Chief Executive Officer781-684-0770


+34 91 515 91

SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies
2. Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020
3. Misonix Announces New Distribution Agreement For Spain
4. Huifeng Bio-Pharmaceutical Technology Announces a New Spain Order
5. Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian
6. For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
9. DFINE StabiliT® Vertebral Augmentation System Product Innovation Offers Physicians Improved Flexibility and Ease-of-Use for the Treatment of Spinal Fractures
10. Medication Delivery Innovator Baxa Corporation Offers Best Practices for Administering Over-the-Counter Liquid Medicine to Babies and Toddlers
11. XTRAC Laser Treatment Offers Summer Time Relief to Psoriasis Sufferers Covered by Major Insurers
Post Your Comments:
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):